FORM 4 [X] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                       
1. Name and Address of Reporting Person * Patel Samir Rashmikant 2. Issuer Name and Ticker or Trading Symbol CytoDyn Inc. [ CYDY ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)         (First)         (Middle)
1111 MAIN STREET SUITE 660		 3. Date of Earliest Transaction (MM/DD/YYYY)
11/24/2021
(Street)
VANCOUVER, WA 98660
(City)       (State)       (Zip)
 4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
 6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Non-qualified Stock Option  $1.39  11/24/2021    D (1)       225000    (1) 10/18/2031  Common Stock  225000   (1) 0  D   
Non-qualified Stock Option  $1.39  11/24/2021    A (1)    93750       (1) 10/18/2031  Common Stock  93750   (1) 93750  D   
Non-qualified Stock Option  $6.15  11/24/2021    D (1)       225000    (2) 6/25/2030  Common Stock  225000   (1) 0  D   
Non-qualified Stock Option  $6.15  11/24/2021    A (1)    225000       (2) 6/25/2030  Common Stock  225000   (1) 225000  D   
Non-qualified Stock Option  $2.25  11/24/2021    D (1)       12329   5/31/2020  4/17/2030  Common Stock  12329   (1) 0  D   
Non-qualified Stock Option  $2.25  11/24/2021    A (1)    12329      5/31/2020  4/17/2030  Common Stock  12329   (1) 12329  D   

Explanation of Responses:
(1)  The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the "2012 Plan")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on November 30, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service.
(2)  56,250 shares vested on August 31, 2020; the balance vested in equal amounts on November 30, 2020, February 28, 2021, and May 31, 2021.

Remarks:
Exhibit 24-Power of Attorney

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Patel Samir Rashmikant
1111 MAIN STREET SUITE 660
VANCOUVER, WA 98660		 X



Signatures
Antonio Migliarese, Attorney-In-Fact 11/29/2021
**Signature of Reporting Person Date
CytoDyn (QB) (USOTC:CYDY)
Historical Stock Chart
From Feb 2023 to Mar 2023 Click Here for more CytoDyn (QB) Charts.
CytoDyn (QB) (USOTC:CYDY)
Historical Stock Chart
From Mar 2022 to Mar 2023 Click Here for more CytoDyn (QB) Charts.